Increased burden of disease and role of health economics: Asia-pacific region

References

• Tran BX, Nong VM, Maher RM, et al. A systematic review of scope and quality of health economic evaluation studies in Vietnam. PLoS One. 2014;9(8):e103825.
   PubMed Web of Science ®Google Scholar
• Kamae I. Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia. Pharmacoeconomics. 2010;28(10):831–838.
   PubMed Web of Science ®Google Scholar
• Tarn YH, Hu S, Kamae I, et al. Health‐care systems and pharmacoeconomic research in Asia‐Pacific region. Value Health. 2008;11:S137–S155.
   PubMed Web of Science ®Google Scholar
• Organization WH. Global tuberculosis report 2015. World Health Organization; 2015.
   Google Scholar
• Kankeu HT, Saksena P, Xu K, et al. The financial burden from non-communicable diseases in low-and middle-income countries: a literature review. Health Res Policy Syst. 2013;11(1):31.
   PubMedGoogle Scholar
• Association AH. Cardiovascular disease: A costly burden for America projections through. Vol. 2035. Washington DC: American Heart Association; 2017.
   Google Scholar
• Dunbar SB, Khavjou OA, Bakas T, et al. Projected costs of informal caregiving for cardiovascular disease: 2015 to 2035: a policy statement from the American Heart Association. Circulation. 2018;137(19):e558–e577.
   PubMed Web of Science ®Google Scholar
• Adeyi O, Smith O, Robles S. Public policy & the challenge of chronic noncommunicable diseases. Washington (DC): The World Bank; 2007.
   Google Scholar
• Miranda JJ, Kinra S, Casas JP, et al. Non‐communicable diseases in low‐and middle‐income countries: context, determinants and health policy. Trop Med Int Health. 2008;13(10):1225–1234.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106(3):388–391.
   PubMed Web of Science ®Google Scholar
• Morgen CS, Rokholm B, Brixval CS, et al. Trends in prevalence of overweight and obesity in Danish infants, children and adolescents–are we still on a plateau? PloS One. 2013;8(7):e69860.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128.
   PubMed Web of Science ®Google Scholar
• Abubakar I, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385(9963):117–171.
   PubMed Web of Science ®Google Scholar
• Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization; 2011.
   Google Scholar
• Levenson JW, Skerrett PJ, Gaziano JM. Reducing the global burden of cardiovascular disease: the role of risk factors. Prev Cardiol. 2002;5(4):188–199.
   PubMedGoogle Scholar
• Moran AE, Roth GA, Narula J, et al. 1990–2010 global cardiovascular disease atlas. Glob Heart. 2014;9(1):3–16.
   PubMedGoogle Scholar
• Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med. 2013;369(14):1336–1343.
   PubMed Web of Science ®Google Scholar
• Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2224–2260.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global burden of disease study 2010. Lancet. 2012;380(9859):2197–2223.
   PubMed Web of Science ®Google Scholar
• Khowaja LA, Khuwaja AK, Cosgrove P. Cost of diabetes care in out-patient clinics of Karachi, Pakistan. BMC Health Serv Res. 2007;7(1):189.
   PubMedGoogle Scholar
• Gillani AH, Aziz MM, Masood I, et al. Direct and indirect cost of diabetes care among patients with type 2 diabetes in private clinics: a multicenter study in Punjab, Pakistan. In: Annemans L, editors. Expert review of pharmacoeconomics & outcomes research. Belgium: Taylor and Francis; 2018. p. 1–7.
   Google Scholar
• Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293–301.
   PubMed Web of Science ®Google Scholar
• Javanbakht M, Baradaran HR, Mashayekhi A, et al. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PloS One. 2011;6(10):e26864.
   PubMed Web of Science ®Google Scholar
• Ali A, Iqbal F, Taj A, et al. Prevalence of microvascular complications in newly diagnosed patients with type 2 diabetes. Pak J Med Sci. 2013;29(4):899.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Snehalatha C, Vijay V, et al. Impact of poverty on the prevalence of diabetes and its complications in urban southern India. Diabetic Med. 2002;19(2):130–135.
   PubMed Web of Science ®Google Scholar
• Ul Haq N, Hassali MA, Shafie AA, et al. A cross sectional assessment of knowledge, attitude and practice towards Hepatitis B among healthy population of Quetta, Pakistan. BMC Public Health. 2012;12(1):692.
   PubMedGoogle Scholar
• Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–149.
   PubMed Web of Science ®Google Scholar
• Federation ID. IDF diabetes atlas. Brussels, Belgium: International Diabetes Federation; 2013.
   Google Scholar
• McIntyre D, Thiede M, Dahlgren G, et al. What are the economic consequences for households of illness and of paying for health care in low-and middle-income country contexts? Soc Sci Med. 2006;62(4):858–865.
   PubMed Web of Science ®Google Scholar
• Russell S. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg. 2004;71(2_suppl):147–155.
   PubMed Web of Science ®Google Scholar
• Bates I, Fenton C, Gruber J, et al. Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants operating at individual and household level. Lancet Infect Dis. 2004;4(5):267–277.
   PubMed Web of Science ®Google Scholar
• Organization WH. Global tuberculosis control: surveillance. planning, financing: WHO Report 2007. World Health Organization; 2007.
   Google Scholar
• Tanimura T, Jaramillo E, Weil D, et al. Financial burden for tuberculosis patients in low-and middle-income countries: a systematic review. Eur Respir J. 2014;43:erj01934–2013.
   Web of Science ®Google Scholar
• Aspler A, Menzies D, Oxlade O, et al. Cost of tuberculosis diagnosis and treatment from the patient perspective in Lusaka, Zambia. Int J Tuberc Lung Dis. 2008;12(8):928–935.
   PubMed Web of Science ®Google Scholar
• Floyd K, Blanc L, Raviglione M, et al. Resources required for global tuberculosis control. Science. 2002;295(5562):2040–2041.
   PubMed Web of Science ®Google Scholar
• Organization WH. Towards a TB free future. Geneva: WHO/CDS/STB; 2001.
   Google Scholar
• Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: A meta-analytic approach. Epilepsia. 2010;51(5):883–890.
   PubMed Web of Science ®Google Scholar
• Mac TL, Tran D-S, Quet F, et al. Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review. Lancet Neurol. 2007;6(6):533–543.
   PubMed Web of Science ®Google Scholar
• Nayel MH. Mutual benefits from epilepsy surgery in developed and developing countries. Epilepsia. 2000;41:S28–S30.
   PubMed Web of Science ®Google Scholar
• Krishnan RA, Chowdhury D. Cost of antiepileptic drugs in India. Neurol Asia. 2007;12(Supplement 1):42–43.
   Google Scholar
• Hesdorffer DC, Beck V, Begley CE, et al. Research implications of the Institute of Medicine Report, epilepsy across the spectrum: promoting health and understanding. Epilepsia. 2013;54(2):207–216.
   PubMed Web of Science ®Google Scholar
• Pi X, Zhou L, Cui L, et al. Prevalence and clinical characteristics of active epilepsy in southern Han Chinese. Seizure. 2014;23(8):636–640.
   PubMed Web of Science ®Google Scholar
• Uthara S, Basheer M, Babu A. A review on cost effective analysis of antiepileptic drugs. Int J Bioassays. 2017;6(9):5507–5512.
   Google Scholar
• Trask LS. Pharmacoeconomics: principles, methods, and applications. In: Pharmacotherapy: A Pathophysiologic Approach. 8th.New York: McGraw-Hill Global Education Holdings; 2011;1–36. Available from: http://accesspharmacy mhmedical com/content aspx
   Google Scholar
• Walker R. Clinical pharmacy and therapeutics E-Book. London: Elsevier Health Sciences; 2011.
   Google Scholar
• Khattak SK, Mehsud SU, Haider IZ, et al. A pharmacoeconomic study in two tertiary care hospitals in Abbottabad. J Ayub Med Coll Abbottabad. 2012;24(2):147–149.
   PubMedGoogle Scholar
• Sanchez L. Conducting pharmacoeconomic evaluations in a hospital setting. Hosp Pharm. 1995;30(5):412–415.
   PubMedGoogle Scholar
• Doherty J, Kamae I, Lee KK, et al. What is next for pharmacoeconomics and outcomes research in Asia? Value Health. 2004;7(2):118–132.
   PubMed Web of Science ®Google Scholar
• Zaidi S, Prasad B, Mathur K. A socio-medical study of male industrial workers along with their families covered under the employees’ state insurance scheme in Aishbagh, Lucknow. Ind J Med Sci. 1970;24(5):272.
   PubMedGoogle Scholar
• Jooma R, Jalal S. Designing the first ever health insurance for the poor in Pakistan–a pilot project. J Pak Med Assoc. 2012;61(1):56.
   Google Scholar
• Dang A, Likhar N, Alok U. Importance of economic evaluation in health care: an Indian perspective. Value Health Reg Issues. 2016;9:78–83.
   PubMedGoogle Scholar
• Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics. 2010;28(12):1069–1074.
   PubMed Web of Science ®Google Scholar
• Tsui AH. Asian wellness in decline: a cost of rising prosperity. Int J Workplace Health Manag. 2008;1(2):123–135.
   Google Scholar
• Misra A, Tandon N, Ebrahim S, et al. Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: current status and future directions. bmj. 2017;357:j1420.
   PubMedGoogle Scholar
• Zhang X, Lu Z, Liu L. Coronary heart disease in China. Heart. 2008;94(9):1126–1131.
   PubMed Web of Science ®Google Scholar
• Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–1518.
   PubMed Web of Science ®Google Scholar
• Aryal KK, Mehata S, Neupane S, et al. The burden and determinants of non communicable diseases risk factors in Nepal: findings from a nationwide STEPS survey. PloS One. 2015;10(8):e0134834.
   PubMed Web of Science ®Google Scholar
• Rahman MM, Gilmour S, Akter S, et al. Prevalence and control of hypertension in Bangladesh: a multilevel analysis of a nationwide population-based survey. J Hypertens. 2015;33(3):465–472.
   PubMed Web of Science ®Google Scholar
• Irazola VE, Gutierrez L, Bloomfield G, et al. Hypertension prevalence, awareness, treatment, and control in selected LMIC communities: results from the NHLBI/UHG Network of centers of excellence for chronic diseases. Glob Heart. 2016;11(1):47–59.
   PubMed Web of Science ®Google Scholar
• Suhrcke M, Nugent RA, Stuckler D, et al. Chronic disease: an economic perspective. London. 2006.
   Google Scholar
• Arthur M. Institute for Health Metrics and Evaluation. Nurs Stand. 2014;28(42):32.
   PubMedGoogle Scholar
• Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. Jama. 2009;301(20):2129–2140.
   PubMed Web of Science ®Google Scholar
• Nanditha A, Ma RC, Ramachandran A, et al. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care. 2016;39(3):472–485.
   PubMed Web of Science ®Google Scholar
• Zimmet PZ, Magliano DJ, Herman WH, et al. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2014;2(1):56–64.
   PubMed Web of Science ®Google Scholar
• Gluckman PD, Hanson MA, Cooper C, et al. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008;359(1):61–73.
   PubMed Web of Science ®Google Scholar
• Organization WH, Unit WHOMoSA. Global status report on alcohol and health, 2014. World Health Organization; 2014.
   Google Scholar
• Anjana R, Ali M, Pradeepa R, et al. The need for obtaining accurate nationwide estimates of diabetes prevalence in India-rationale for a national study on diabetes. Indian J Med Res. 2011;133(4):369.
   PubMed Web of Science ®Google Scholar
• Shetty P. India’s diabetes time bomb. Nature. 2012;485(7398):S14.
   PubMed Web of Science ®Google Scholar
• Yoon K-H, Lee J-H, Kim J-W, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681–1688.
   PubMed Web of Science ®Google Scholar
• Beagley J, Guariguata L, Weil C, et al. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract. 2014;103(2):150–160.
   PubMed Web of Science ®Google Scholar
• Atlas D. International diabetes federation. In: IDF diabetes atlas, 7th. Brussels, Belgium: International Diabetes Federation;2015:1–44.
   Google Scholar
• Ghaffar A, Reddy KS, Singhi M. Burden of non-communicable diseases in South Asia. BMJ. 2004;328(7443):807.
   PubMedGoogle Scholar
• Chan JC, Cho NH, Tajima N, et al. Diabetes in the Western Pacific Region—past, present and future. Diabetes Res Clin Pract. 2014;103(2):244–255.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Snehalatha C, Ma RCW. Diabetes in south-east Asia: an update. Diabetes Res Clin Pract. 2014;103(2):231–237.
   PubMed Web of Science ®Google Scholar
• Muniyandi M, Ramachandran R. Socioeconomic inequalities of tuberculosis in India. Expert Opin Pharmacother. 2008;9(10):1623–1628.
   PubMed Web of Science ®Google Scholar
• Kazi AM, Shah SA, Jenkins CA, et al. Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan. Inter J Infect Dis. 2010;14:e60–e66.
   PubMed Web of Science ®Google Scholar
• Organization WH. Global tuberculosis report. 2018.
   Google Scholar
• Hussain H, Akhtar S, Nanan D. Prevalence of and risk factors associated with Mycobacterium tuberculosis infection in prisoners, North West Frontier Province, Pakistan. Int J Epidemiol. 2003;32(5):794–799.
   PubMed Web of Science ®Google Scholar
• Organization WH. Global tuberculosis report 2017.
   Google Scholar
• Broekmans J, Caines K, Paluzzi JE. Investing in strategies to reverse the global incidence of TB. London: Earthscan. 2005.
   Google Scholar
• Organization WH. World Health Organization global tuberculosis control report 2009. Global tuberculosis control. 2011.
   Google Scholar
• Jackson S, Sleigh A, Wang G, et al. Poverty and the economic effects of TB in rural China. Int J Tuberc Lung Dis. 2006;10(10):1104–1110.
   PubMed Web of Science ®Google Scholar
• Gopi P, Subramani R, Santha T, et al. Estimation of burden of tuberculosis in India for the year 2000. Indian J Med Res. 2005;122:(Sep):243–248.
   PubMed Web of Science ®Google Scholar
• Rajshekhar V, Raghava MV, Prabhakaran V, et al. Active epilepsy as an index of burden of neurocysticercosis in Vellore district, India. Neurology. 2006;67(12):2135–2139.
   PubMed Web of Science ®Google Scholar
• Das K, Banerjee M, Mondal G, et al. Evaluation of socio-economic factors causing discontinuation of epilepsy treatment resulting in seizure recurrence: a study in an urban epilepsy clinic in India. Seizure. 2007;16(7):601–607.
   PubMed Web of Science ®Google Scholar
• Lim KS, Ng CC, Chan CK, et al. Ethnic variation of genetic (idiopathic) generalized epilepsy in Malaysia. Seizure. 2017;45:24–27.
   PubMed Web of Science ®Google Scholar
• Saeed KMI. Prevalence of risk factors for non-communicable diseases in the adult population of urban areas in Kabul City, Afghanistan. Cent Asian J Glob Health. 2013;2:2.
   Google Scholar
• Akter S, Rahman MM, Abe SK, et al. Prevalence of diabetes and prediabetes and their risk factors among Bangladeshi adults: a nationwide survey. Bull World Health Organ. 2014;92:204–213A.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. Jama. 2013;310(9):948–959.
   PubMed Web of Science ®Google Scholar
• Yesudian CA, Grepstad M, Visintin E, et al. The economic burden of diabetes in India: a review of the literature. Global Health. 2014;10(1):80.
   PubMedGoogle Scholar
• MORIMOTO A, NISHIMURA R, TAJIMA N. Trends in the epidemiology of patients with diabetes in Japan. Japan Med Assoc J. 2010;53.
   Google Scholar
• Wan Nazaimoon W, Md Isa S, Wan Mohamad W, et al. Prevalence of diabetes in Malaysia and usefulness of HbA1c as a diagnostic criterion. Diabetic Med. 2013;30(7):825–828.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Ghimire A, Radhakrishnan J, et al. Prevalence of hypertension, obesity, diabetes, and metabolic syndrome in Nepal. Int J Hypertens. 2011;2011.
   Google Scholar
• Guariguata L, Nolan T, Beagley J. International diabetes federation. In: Guariguata L, editor. IDF diabetes atlas. Brussels: International Diabetes Federation; 2014:1–160.
   Google Scholar
• Jayawardena R, Ranasinghe P, Byrne NM, et al. Prevalence and trends of the diabetes epidemic in South Asia: a systematic review and meta-analysis. BMC Public Health. 2012;12(1):380.
   PubMedGoogle Scholar
• Deerochanawong C, Ferrario A. Diabetes management in Thailand: a literature review of the burden, costs, and outcomes. Global Health. 2013;9(1):11.
   PubMedGoogle Scholar
• Aekplakorn W, Chariyalertsak S, Kessomboon P, et al. Thai national health examination survey IV study group: prevalence and management of diabetes and metabolic risk factors in Thai adults: the Thai national health examination survey IV, 2009. Diabetes Care. 2011;34(9):1980–1985.
   PubMed Web of Science ®Google Scholar
• McKeigue P, Shah B, Marmot M. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet. 1991;337(8738):382–386.
   PubMed Web of Science ®Google Scholar
• Collaboration APCS. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21(4):707–716.
   PubMed Web of Science ®Google Scholar
• Ohira T, Iso H. Cardiovascular disease epidemiology in Asia. Circ J. 2013;77(7):1646–1652.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ward AJ, O’Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care. 2002;25(3):476–481.
   PubMed Web of Science ®Google Scholar
• Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med. 2013;45(3):253–261.
   PubMed Web of Science ®Google Scholar
• Lim K-S, Tan C-T. Epilepsy stigma in Asia: the meaning and impact of stigma. Neurol Asia. 2014;19:1.
   Web of Science ®Google Scholar
• Mbuba CK, Ngugi AK, Newton CR, et al. The epilepsy treatment gap in developing countries: A systematic review of the magnitude, causes, and intervention strategies. Epilepsia. 2008;49(9):1491–1503.
   PubMed Web of Science ®Google Scholar
• Bloom G, Katsuma Y, Rao KD, et al. Next steps towards universal health coverage call for global leadership. BMJ. 2019;365:l2107.
   PubMed Web of Science ®Google Scholar
• Organization WH. WHO. South East Asia J Public Health. 2019 April;8(1):1–65.
   Google Scholar
• Sinnott S-J, Buckley C, David O, et al. The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PloS One. 2013;8(5):e64914.
   PubMed Web of Science ®Google Scholar
• Low W-Y, Lee Y-K, Samy AL. Non-communicable diseases in the Asia-Pacific region: prevalence, risk factors and community-based prevention. Int J Occup Med Environ Health. 2015;28:1–7.
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. Jama. 2008;300(21):2514–2526.
   PubMed Web of Science ®Google Scholar
• Cameron A, Mantel-Teeuwisse AK, Leufkens HG, et al. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health. 2012;15(5):664–673.
   PubMed Web of Science ®Google Scholar
• Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240–249.
   PubMed Web of Science ®Google Scholar
• OHalloran L, Slattery M. Assessing the knowledge of cardiovascular disease among young people in South Dublin. Cardiol Cardiovasc Med. 2017;1(4):187–194.
   Google Scholar
• Barquera S, Pedroza-Tobías A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46(5):328–338.
   PubMed Web of Science ®Google Scholar
• Gaziano TA, Bitton A, Anand S, et al. Growing epidemic of coronary heart disease in low-and middle-income countries. Curr Probl Cardiol. 2010;35(2):72–115.
   PubMed Web of Science ®Google Scholar
• Huffman MD, Rao KD, Pichon-Riviere A, et al. A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low-and middle-income countries. PloS One. 2011;6(6):e20821.
   PubMed Web of Science ®Google Scholar
• Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368–376.
   PubMed Web of Science ®Google Scholar
• Le C, Zhankun S, Jun D, et al. The economic burden of hypertension in rural south‐west China. Trop Med Int Health. 2012;17(12):1544–1551.
   PubMed Web of Science ®Google Scholar
• Shrestha N, Lohani SP, Angdembe MR, et al. Cost of diabetes mellitus care among patients attending selected outpatient clinics. J Nepal Med Assoc. 2013;52:190.
   Web of Science ®Google Scholar
• Kumpatla S, Kothandan H, Tharkar S, et al. The costs of treating long term diabetic complications in a developing country: a study from India. JAPI. 2013;61:17.
   Google Scholar
• Li H, Chen B, Shah N, et al. Socioeconomic correlates of inpatient spending for patients with type 2 diabetes mellitus in China: evidence from Hangzhou. Exp Clin Endocrinol Diabetes. 2012;120(01):35–44.
   PubMedGoogle Scholar
• Zhao W, Zhai Y, Hu J, et al. Economic burden of obesity‐related chronic diseases in Mainland China. Obesity Rev. 2008;9:62–67.
   PubMed Web of Science ®Google Scholar
• Ross H, Trung DV, Phu VX. The costs of smoking in Vietnam: the case of inpatient care. Tob Control. 2007;16(6):405–409.
   PubMed Web of Science ®Google Scholar
• Nordin N, Aljunid S, Aziz N, et al. Direct medical cost of stroke: findings from a tertiary hospital in Malaysia. Malays J Med Sci. 2012;67:5.
   Google Scholar
• Zubair MT, Enam SA, Pervez RA, et al. Cost-effectiveness of clipping vs coiling of intracranial aneurysms after subarachnoid hemorrhage in a developing country–a prospective study. Surg Neurol. 2009;72(4):355–360. discussion 360–1.
   PubMedGoogle Scholar
• Asil T, Celik Y, Sut N, et al. Cost of acute ischemic and hemorrhagic stroke in Turkey. Clin Neurol Neurosurg. 2011;113(2):111–114.
   PubMed Web of Science ®Google Scholar
• Malhotra S, Karan R, Pandhi P, et al. Pattern of use and pharmacoeconomic impact of antihypertensive drugs in a north Indian referral hospital. Eur J Clin Pharmacol. 2001;57(6–7):535–539.
   PubMed Web of Science ®Google Scholar
• Jhaj R, Goel N, Gautam C, et al. Prescribing patterns and cost of antihypertensive drugs in an internal medicine clinic. Indian Heart J. 2001;53(3):323–327.
   PubMedGoogle Scholar
• Malhotra S, Grover A, Verma N, et al. A study of drug utilisation and cost of treatment in patients hospitalised with unstable angina. Eur J Clin Pharmacol. 2000;56(9–10):755–761.
   PubMed Web of Science ®Google Scholar
• Rao KD, Bhatnagar A, Murphy A. Socio-economic inequalities in the financing of cardiovascular & diabetes inpatient treatment in India. Indian J Med Res. 2011;133(1):57.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Mohanty SK. Age and sex pattern of cardiovascular mortality, hospitalisation and associated cost in India. PloS One. 2013;8(5):e62134.
   PubMed Web of Science ®Google Scholar
• Khealani B, Javed Z, Syed N, et al. Cost of acute stroke care at a tertiary care hospital in Karachi, Pakistan. J Pak Med Assoc. 2003;53(11):552.
   PubMedGoogle Scholar
• Kwatra G, Kaur P, Toor G, et al. Cost of stroke from a tertiary center in northwest India. Neurol India. 2013;61(6):627.
   PubMed Web of Science ®Google Scholar
• Marfatia S, Monz B, Suvarna V, et al. Treatment costs of stroke related to nonvalvular atrial fibrillation patients in India—a multicenter observational study. Value Health Reg Issues. 2014;3:205–210.
   PubMedGoogle Scholar
• Abegunde DO, Mathers CD, Adam T, et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007;370(9603):1929–1938.
   PubMed Web of Science ®Google Scholar
• Egan AM, Dinneen SF. What is diabetes? Medicine (Baltimore). 2014;42(12):679–681.
   Google Scholar
• Henriques RS, Steimbach LM, Baptista DR, et al. DIRECT COSTS OF TYPE 2 DIABETES: A BRAZILIAN COST-OF-ILLNESS STUDY. Int J Technol Assess Health Care. 2018;34(2):180–188.
   PubMed Web of Science ®Google Scholar
• Chandra P, Gogate B, Gogate P, et al. Economic burden of diabetes in urban Indians. Open Ophthalmol J. 2014;8:91.
   PubMedGoogle Scholar
• Kapur A. Economic analysis of diabetes care. Indian J Med Res. 2007;125(3):473.
   PubMed Web of Science ®Google Scholar
• Kumar A, Nagpal J, Bhartia A. Direct cost of ambulatory care of type 2 diabetes in the middle and high income group populace of Delhi: the DEDICOM survey. JAPI. 2008;56:667–674.
   Google Scholar
• Rayappa P, Raju K, Kapur A, et al. Economic cost of diabetes care: the Bangalore urban district diabetes study. Int J Diab Dev Countries. 1999;19(3):87–96.
   Google Scholar
• Shobhana R, Rao PR, Lavanya A, et al. Expenditure on health care incurred by diabetic subjects in a developing country—a study from southern India. Diabetes Res Clin Pract. 2000;48(1):37–42.
   PubMed Web of Science ®Google Scholar
• Walker IF, Garbe F, Wright J, et al. The economic costs of cardiovascular disease, diabetes mellitus, and associated complications in South Asia: a systematic review. Value Health Reg Issues. 2018;15:12–26.
   PubMedGoogle Scholar
• Tharkar S, Satyavani K, Viswanathan V. Cost of medical care among type 2 diabetic patients with a co-morbid condition—hypertension in India. Diabetes Res Clin Pract. 2009;83(2):263–267.
   PubMed Web of Science ®Google Scholar
• Ali S, Fareed A, Humail S, et al. The personal cost of diabetic foot disease in the developing world—a study from Pakistan. Diabetic Med. 2008;25(10):1231–1233.
   PubMed Web of Science ®Google Scholar
• Clarke PM, Glasziou P, Patel A, et al. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med. 2010;7(2):e1000236.
   PubMed Web of Science ®Google Scholar
• Tharkar S, Devarajan A, Kumpatla S, et al. The socioeconomics of diabetes from a developing country: a population based cost of illness study. Diabetes Res Clin Pract. 2010;89(3):334–340.
   PubMed Web of Science ®Google Scholar
• Shastry R, Ullal SD, Bethi Y, et al. Cost analysis of drugs used in elderly patients with cardiovascular disorder. Res J Pharm Biol Chem Sci. 2015;6(1):83–86.
   Google Scholar
• Sharma D, Sarkar D. Pathophysiology of tuberculosis: an update review. PharmaTutor. 2018;6:15–21.
   Google Scholar
• Tiberi S, Petersen E, Maeurer M, et al. Taking forward the stop TB partnership and world health organization joint theme for world TB day march 24th 2018—“wanted: leaders for a TB-free world. You can make history. End TB”. London: Elsevier; 2018.
   Google Scholar
• Organization WH. Treatment of tuberculosis: guidelines for national programmes. Geneva: World Health Organization; 1993.
   Google Scholar
• Rubado DJ, Choi D, Becker T, et al. Determining the cost of tuberculosis case management in a low-incidence state. Int J Tuberc Lung Dis. 2008;12(3):301–307.
   PubMed Web of Science ®Google Scholar
• Diel R, Rappenhöner B, Schaberg T. The cost structure of lung tuberculosis in Germany. Eur J Health Econ. 2004;5(3):243–251.
   PubMedGoogle Scholar
• Othman G, Raja’a Y. Costs associated with tuberculosis diagnosis and treatment in Yemen for patients and public health services. East Mediterr Health J. 2012;18:393–398.
   Google Scholar
• Pantoja A, Floyd K, Unnikrishnan K, et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients. Int J Tuberc Lung Dis. 2009;13(6):698–704.
   PubMed Web of Science ®Google Scholar
• Iqbal M, Iqbal M, Bahari M, et al. a pharmacoeconomic care analysis of tuberculosis control in Pakistan. Value Health. 2014;17(7):A594.
   Web of Science ®Google Scholar
• Rizvi M, Naqvi B, Abbas A. Financial burden of pulmonary tuberculosis (TB) in Pakistan. World J Pharm Res. 2015;4:65–78.
   Google Scholar
• Atif M, Sulaiman SAS, Shafie AA, et al. Resource utilization pattern and cost of tuberculosis treatment from the provider and patient perspectives in the state of Penang, Malaysia. BMC Health Serv Res. 2014;14(1):353.
   PubMedGoogle Scholar
• Rajeswari R, Balasubramanian R, Muniyandi M, et al. Socio-economic impact of tuberculosis on patients and family in India. Int J Tuberc Lung Dis. 1999;3(10):869–877.
   PubMed Web of Science ®Google Scholar
• Ayé R, Wyss K, Abdualimova H, et al. Household costs of illness during different phases of tuberculosis treatment in Central Asia: a patient survey in Tajikistan. BMC Public Health. 2010;10(1):18.
   PubMedGoogle Scholar
• Elamin EI, Ibrahim MIM, Sulaiman SAS, et al. Cost of illness of tuberculosis in Penang, Malaysia. Pharm World Sci. 2008;30(3):281–286.
   PubMedGoogle Scholar
• Laurence YV, Griffiths UK, Vassall A. Costs to health services and the patient of treating tuberculosis: a systematic literature review. Pharmacoeconomics. 2015;33(9):939–955.
   PubMed Web of Science ®Google Scholar
• Floyd K, Arora V, Murthy K, et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ. 2006;84:437–445.
   PubMed Web of Science ®Google Scholar
• Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. Bmj. 2003;326(7389):574.
   PubMedGoogle Scholar
• Suen S, Bendavid E, Goldhaber-Fiebert JD. Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India. Int J Tuberc Lung Dis. 2015;19(9):1115–1124.
   PubMed Web of Science ®Google Scholar
• Pethani A, Zafar M, Khan AA, et al. Engaging general practitioners in public–private mix tuberculosis DOTS program in an urban area in Pakistan: need for context-specific approach. Asia Pac J Public Health. 2015;27(2):NP984–NP992.
   PubMed Web of Science ®Google Scholar
• Johns B, Probandari A, Mahendradhata Y, et al. An analysis of the costs and treatment success of collaborative arrangements among public and private providers for tuberculosis control in Indonesia. Health Policy. 2009;93(2–3):214–224.
   PubMed Web of Science ®Google Scholar
• Kibuule D, Verbeeck RK, Nunurai R, et al. Predictors of tuberculosis treatment success under the DOTS program in Namibia. Expert Rev Respir Med. 2018;12(11):979–987.
   PubMed Web of Science ®Google Scholar
• Kibuule D, Rennie T, Ruswa N, et al. Effectiveness of community-based DOTS strategy on tuberculosis treatment success rates in Namibia. Int J Tuberc Lung Dis. 2019;23(4):441–449.
   PubMed Web of Science ®Google Scholar
• Amudhan S, Gururaj G, Satishchandra P. Epilepsy in India II: impact, burden, and need for a multisectoral public health response. Ann Indian Acad Neurol. 2015;18(4):369.
   PubMed Web of Science ®Google Scholar
• Thomas S, Sarma P, Alexander M, et al. Economic burden of epilepsy in India. Epilepsia. 2001;42(8):1052–1060.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan K, Nayak SD, Kumar SP, et al. Profile of antiepileptic pharmacotherapy in a tertiary referral center in South India: a pharmacoepidemiologic and pharmacoeconomic study. Epilepsia. 1999;40(2):179–185.
   PubMed Web of Science ®Google Scholar
• Hong Z, Qu B, Wu XT, et al. Economic burden of epilepsy in a developing country: a retrospective cost analysis in China. Epilepsia. 2009;50(10):2192–2198.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Z, Meng F. The economic burden of epilepsy in a sample of people with epilepsy in China. Epilepsy Res. 2013;103(2–3):288–293.
   PubMed Web of Science ®Google Scholar
• Krishnan A, SuA S, Kapoor SK. Cost of epilepsy in patients attending a secondary‐level hospital in India. Epilepsia. 2004;45(3):289–291.
   PubMed Web of Science ®Google Scholar
• Haroon A, Tripathi M, Khanam R, et al. Antiepileptic drugs prescription utilization behavior and direct costs of treatment in a national hospital of India. Ann Indian Acad Neurol. 2012;15(4):289.
   PubMed Web of Science ®Google Scholar
• Habib M, Khan SU, Hoque MA, et al. Antiepileptic drug utilization in Bangladesh: experience from dhaka medical college hospital. BMC Res Notes. 2013;6(1):473.
   PubMedGoogle Scholar